Thesis pillars
- Customer Concentration Risk↑Improving
- Declining Revenue→Stable
- Price Above Analyst Target→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Feb 26, 2026
Fortrea Holdings Inc. (FTRE) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $25.88: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Below-average business quality.
Fortrea Holdings Inc. is a global contract research organization providing phase I-IV clinical trial management, clinical pharmacology, and consulting services to pharmaceutical, biotechnology, and medical device customers across more than 20 therapeutic areas. The company... Read more
Sell if holding. Engine safety override at $25.88: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.9/10, moderate confidence.
Passes 5/7 gates (positive momentum, clean insider activity, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Fortrea Holdings Inc.
About Fortrea Holdings Inc.
Fortrea Holdings' backlog stood at $7.7 billion as of December 31, 2025, built by a single Clinical Services segment spanning phase I through IV clinical trials, clinical pharmacology, and consulting for pharmaceutical, biotechnology, and medical device customers across more than 20 therapeutic areas. The company employs approximately 14,300 people across roughly 100 countries, and its top ten customers accounted for approximately 57% of 2025 revenue, with one customer alone contributing approximately 18.1%.
Fortrea earns revenue through three delivery models -- Full Service (integrated, project-centric), Functional Service Provider (staffing customers' internal programs), and Hybrid -- with Clinical Development, its largest offering for five consecutive years, covering regulatory affairs, patient recruitment, data management, and pharmacovigilance. Clinical Pharmacology operates four clinical research units in Leeds (U.K.), Dallas, Daytona Beach, and Madison, together offering roughly 376 beds for first-in-human and label-support studies. Oncology represented 40% of full-service therapeutic-based revenue in 2025, the company's largest single therapeutic concentration, built on more than 1,200 completed oncology trials over the prior five years. Fortrea also depends on strategic technology partners including Advarra, Cognizant, Medidata, and Veeva for the data and digital infrastructure underlying its trials, and remains subject to continuing contingent liabilities and indemnification obligations stemming from its 2023 spin-off from Labcorp.
Show full overview
Fortrea's customer base has grown more concentrated over time, not less: its top 20 customers rose from 61% of revenue in 2023 to 64% in 2024 and 69% in 2025, even as the company describes its base as large and diversified. That concentration compounds a structural contract risk -- once a project goes to contract, most customers can terminate without cause on 30 to 90 days' notice, and Fortrea's own backlog of $7.7 billion is explicitly not a reliable predictor of future revenue given the company's history of project delays, cancellations, and scope reductions.
See also: Healthcare · Biotechnology
From Fortrea Holdings Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Fortrea Holdings Inc.
Latest news
- NEWS Fortrea Holdings Raises FY2026 Sales Guidance from $2.620B-$2.690B to $2.665B-$2.690B vs $2.663B Est — benzinga Oct 29, 2026 positive
- NEWS Fortrea Holdings Q3 Adj. EPS $0.28 Beats $0.22 Estimate, Sales $691.500M Beat $669.951M Estimate — benzinga Oct 29, 2026 positive
- NEWS Fortrea to Participate in Jefferies Global Healthcare Conference — fiscal.ai Oct 27, 2026
- NEWS Fortrea and Omico Announce Collaboration to Advance Precision Oncology Research — fiscal.ai Oct 22, 2026 positive
- NEWS Fortrea And Omico Collaborate To Accelerate Precision Oncology Research By Helping Connect Cancer Patients To Biomarker- — benzinga Oct 22, 2026 positive
Generated 2026-10-29T11:14:32Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWCustomerone customer18%10-K Item 1: 'As of the fiscal year ended 2025, one customer accounted for approximately 18.1% of our revenue'
- HIGHCustomertop ten customers57%10-K Item 1A: 'our top ten customers based on revenue accounted for approximately 57% of our consolidated revenue'
- HIGHCustomertop 20 customers69%10-K Item 1: 'Our top 20 customers represented approximately 69% of total revenue for 2025'
- MEDIUMProductoncology40%10-K Item 1: 'In 2025, 40% of our full service therapeutic-based revenue related to oncology studies'
Material Events(8-K, last 90d)
- 2026-06-26Item 5.02MEDIUMEffective July 6, 2026, Jason Knoblauch (previously EVP & CFO of Clario) will become Fortrea's CFO, succeeding Jill McConnell, who steps down as CFO on that date but will remain employed during a transition period.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Unprofitable operations — net margin -3.2%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $25.88: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $24.07. Score 4.9/10, moderate confidence.
Analyst target $18.89 reached (−27.0% from $25.88); no take-profit level is published. Prior stop was $24.07. Stop-loss: $24.07.
Concentration risk — Customer: top ten customers (57.0%); Concentration risk — Customer: top 20 customers (69.0%); Target reached (-27.0% upside).
Fortrea Holdings Inc. trades at a P/E of N/A (forward 22.9). TrendMatrix value score: 5.7/10. Verdict: Sell.
18 analysts cover FTRE with a consensus score of 3.7/5. Average price target: $22.
What does Fortrea Holdings Inc. do?Fortrea Holdings Inc. is a global contract research organization providing phase I-IV clinical trial management,...
Fortrea Holdings Inc. is a global contract research organization providing phase I-IV clinical trial management, clinical pharmacology, and consulting services to pharmaceutical, biotechnology, and medical device customers across more than 20 therapeutic areas. The company employs approximately 14,300 people operating in about 100 countries, reports as a single Clinical Services segment, and had a backlog of $7.7 billion as of December 31, 2025; one customer accounted for approximately 18.1% of 2025 revenue, and its top ten customers represented approximately 57%.